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topics, understandability, and feasibility of use. Based on the
above steps, a preliminary instrument was created for valida-
tion testing. RESULTS: Key themes generated from literature,
clinicians, and families included various aspects of pain, difﬁ-
culty using the device, embarrassment, and time involved
affecting productivity, convenience, and compliance. Two ver-
sions of the preference instrument were created to reﬂect the
child and parent perspectives. A 4-point Likert scale was used
for most questions. The child version included 38 survey items
on clarity of instructions (2), preparation (7), administration
(4), convenience (3), pain (5), embarrassment (2), anxiety (2),
productivity (4), compliance (3), mood (1), and overall satis-
faction (5). All items from the child questionnaire were
included in the parent version, supplemented with ﬁve ques-
tions regarding administration, parent productivity, and parent
overall satisfaction. CONCLUSION: Areas of concern for fami-
lies using GH delivery devices include pain, productivity, and
convenience. This new instrument, which may offer clinicians
and researchers an opportunity to evaluate different device
alternatives for GH replacement therapy, will soon undergo
formal validation testing.
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OBJECTIVE: To assess the association between the DM-39 and
HbA1c in a large insulin clinical trial (acronym: DURABLE)
where HbA1c is a primary efﬁcacy endpoint. METHODS: The
DURABLE trial enrolled insulin-naïve type 2 diabetes patients
then randomized them to lispro mix 75/25 bid or glargine qd.
Trial participants completed the DM-39 at baseline prior to
receiving insulin. The DM-39 is a 39-item diabetes-speciﬁc
PRO measure with 5 domains: Energy/Mobility (15-item), Dia-
betes Control (12-item), Anxiety/Worry (4-item), Social Burden
(5-item), and Sexual Function (3-item). Each domain’s score
ranged from 0–100 with a higher score representing worse
PRO. We used Spearman’s correlation to assess the overall
association with HbA1c. We also conducted analysis of vari-
ance (ANOVA) with pairwise comparisons using Scheffe adjust-
ment to compare the mean scores reported by patients with
baseline HbA1c <8.0% (group A); 8.0–8.9% (B); 9.0–9.9%
(C); and >10% (D). RESULTS: A trial subgroup of 867
patients (mean age = 56.8 years, duration of diabetes = 9.6
years, HbA1c = 8.9%. 42% female, 65% Caucasian) provided
the data. Correlations with HbA1c were low (r range: 0.01–
0.18) with Diabetes Control (r = 0.18), Anxiety/Worry
(r = 0.10), and Social Burden (r = 0.11) resulting in statistically
signiﬁcant correlations (p < 0.01). Overall ANOVA p-values
were statistically signiﬁcant for Diabetes Control (mean scores
for groups A, B, C, and D = 37.5, 39.7, 43.7, and 46.2, respec-
tively, p < 0.001); Anxiety/Worry (41.5, 42.2, 48.5, and 47.0,
p = 0.003); and Social Burden (22.2, 21.6, 25.5, and 28.3,
p < 0.001). Pairwise comparisons were statistically signiﬁcant
for Diabetes Control (A vs. C, A vs. D, and B vs. D); Anxiety/
Worry (A vs. C); and Social Burden (A vs. D and B vs. D).
CONCLUSION: DM-39 is weakly associated with HbA1c.
However, our ﬁndings suggest that some targeted domains (e.g.,
Diabetes Control) may be useful in assessing the changes in
PRO for clinical trials evaluating insulin initiation with a
primary endpoint of HbA1c.
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OBJECTIVE: The study evaluated the impact of a doctor’s or a
health professional’s instructions on lifestyle behaviors among
the US adult diabetic population. METHODS: The study popu-
lation was adult diabetic subjects in the latest National Health
and Nutrition Examination Survey (NHANES) 2005–2006.
Multivariate logistic regression was employed adjusting for the
survey design using STATA software. A total of 459 diabetic
subjects aged 18 and over were enrolled, which represented
about 15 million US adults with diabetes. The three dichotomous
categorical independent variables of interest were whether the
subject had been told by their doctor or health professional in the
last year to lower their risk of certain diseases by controlling
weight, by increasing physical activity, or by reducing fat or
calorie intake. The outcomes of interest were whether action was
currently being taken by the subject to follow that past advice.
RESULTS: After controlling potential confounders (including
demographics, education, and disease severity), it was found that
subjects who were told by their doctor or health professional to
lose weight were more likely to be working on weight control,
compared with those not told to do so (p < 0.001). Similar results
were found for exercise advice (p = 0.001) and diet advice
(p = 0.002). This cross-sectional analysis cannot conﬁrm causal-
ity and recall bias cannot be eliminated. CONCLUSION: The
study suggests that advice by a doctor or a health professional
has great impact on diabetic patients to take actions in changing
their lifestyle behaviors.
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OBJECTIVE: Differences between patient-rated importance of
insulin delivery system (IDS) features and patient evaluation of
those features in current IDS may contribute to patient satisfac-
tion. This study aimed to examine: 1) the importance of 12 IDS
features to patients with type 2 diabetes (T2DM); 2) the dis-
crepancies between feature importance and patient evaluation
of those features in current IDS; 3) the relationship between
discrepancies and IDS satisfaction. METHODS: Patients with
T2DM currently using insulin were administered a web-based
survey including questions on demographics, insulin therapy, and
a modiﬁed Insulin Injection Preference questionnaire (mIIP-q).
ThemIIP-q asks patients to evaluate the extent towhich they agree
their current IDS has each of the 12 features representing 3
components (“ease of use,” “activity interference,” and “social
acceptability”). Patients were also asked to rank and rate the
importance of the 12 IDS features. Discrepancy scores were
calculated by subtracting the feature importance score from the
feature evaluation score. Correlation and stepwise linear regres-
sion analyses were conducted to assess the relationship between
discrepancy scores and IDS satisfaction.RESULTS:A total of 681
patients (48%male, mean age = 57) participated in the survey. All
IDS features in the mIIP-q were considered important (mean
rating >50 on a 0–100 scale). The feature “easy to control blood
sugar” showed the highest discrepancy score, followed by all
“activity interference” features (P < 0.01). Discrepancy scores for
A234 Abstracts
